The latest company news, press releases, and resources about Sunovion–the company, our employees, our partners, and our latest innovations.

Featured News

June 15, 2020

Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes

July 21, 2017

Sunovion’s Latuda® (lurasidone HCI) Receives Health Canada Approval to Treat Adolescents with Schizophrenia

October 15, 2015

Sunovion Celebrates Five-Year Anniversary Milestone

July 11, 2014

Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM™ (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy

September 18, 2013

Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance for Review of the New Drug Submission of eslicarbazepine acetate as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy

September 17, 2012

Sunovion Pharmaceuticals Canada Inc. Announces the Launch of Once-Daily LATUDA™ (lurasidone HCl) for the Treatment of Patients with Schizophrenia

June 15, 2012

Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of Once-Daily LATUDA™ (lurasidone HCl) for the Treatment of Patients with Schizophrenia

August 23, 2011

Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia

 

 

Media Inquiries

For any media inquiries or logo usage requirements, please contact Sunovion Corporate Communications at 508-357-7740 or email corpcomm@sunovion.com